Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.54 USD | -3.42% | -12.41% | -20.13% |
May. 15 | Lumos Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 15 | Transcript : Lumos Pharma, Inc., Q1 2024 Earnings Call, May 15, 2024 |
Financials (USD)
Sales 2024 * | 8.75M | Sales 2025 * | 10.82M | Capitalization | 20.62M |
---|---|---|---|---|---|
Net income 2024 * | -40M | Net income 2025 * | -40M | EV / Sales 2024 * | 2.36 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.9 x |
P/E ratio 2024 * |
-0.78
x | P/E ratio 2025 * |
-1.43
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.97% |
Latest transcript on Lumos Pharma, Inc.
1 day | -3.42% | ||
1 week | -12.41% | ||
Current month | -9.61% | ||
1 month | +0.79% | ||
3 months | -14.19% | ||
6 months | -16.99% | ||
Current year | -20.13% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 2.54 | -3.42% | 7,451 |
24-05-16 | 2.63 | +17.41% | 44,346 |
24-05-15 | 2.24 | -12.16% | 138,072 |
24-05-14 | 2.55 | -11.30% | 85,052 |
24-05-13 | 2.875 | -0.86% | 11,233 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.13% | 20.62M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+28.31% | 12.16B | |
+24.73% | 12.17B |
- Stock Market
- Equities
- LUMO Stock